Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions

Every year, about 700 Danish men get radiotherapy for prostate cancer with a high-risk of later progression. The risk of relapse is about 40 % after 5 - 8 years, so we need better treatment for these patients in Denmark and globally. The aim is to reduce later cancer spreading, need of hormone treatments and prostate cancer death. DAPROCA 10 tests two possible improvements: If a higher dose (boost) to intra-prostatic tumor lesions improves cure rates. If the radiotherapy can be given with 12 treatment fractions instead of 20 without increased side-effects. In this randomised trial half the

Trial Details

NCT ID
NCT07343349
Phase
NA
Sponsor
Copenhagen University Hospital, Rigshospitalet
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Addition of focal boost and hypofractionation
Locations (sample)
  • Aarhus, Denmark|56.15674,10.21076
  • Copenhagen, Denmark|55.67594,12.56553
  • Vejle, Denmark|55.70927,9.5357

Key Eligibility Criteria

  • Patients with biopsy verified PCa with no distant metastases with either
  • Intermediate- or high-risk PCa, defined as at least one of the following risk criteria:
  • Clinical stage cT2c-T3b (UICC TNM 8th edition)
  • Imaging stage, T3a or T3b

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →